[Form 4] Alignment Healthcare, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Alignment Healthcare insider sale under a 10b5-1 plan: Dawn C. Maroney, President and officer of Alignment Healthcare (ALHC), reported a planned disposition of 30,000 shares of common stock on 08/13/2025 at a weighted-average price of $14.9036 per share, executed under a Rule 10b5-1 trading plan adopted 11/25/2024. After the sale, Maroney beneficially owns 2,012,899 shares directly. The filing notes the sale prices ranged from $14.64 to $15.13 and that full allocation details by price will be provided on request.

Positive

• Sale executed under a Rule 10b5-1 plan adopted 11/25/2024, indicating pre-planned and compliant insider trading
• Reporting person retains sizable ownership after the transaction: 2,012,899 shares beneficially owned

Negative

• Officer sold 30,000 shares, which may be viewed by some investors as insider liquidity rather than buy-side conviction

Insights

Financial Analyst

TL;DR: A routine, pre-planned insider sale of 30,000 shares under a 10b5-1 plan; ownership remains material at ~2.01M shares.

The transaction appears to be an orderly disposition executed under a Rule 10b5-1 plan, reducing the reporting person's direct holdings from an unstated prior level to 2,012,899 shares. The reported weighted-average sale price was $14.9036, with individual trades between $14.64 and $15.13. For investors, this filing documents insider liquidity but does not in itself indicate a change in company fundamentals. Materiality is limited given the remaining ownership size and the use of a trading plan.

Corporate Governance Expert

TL;DR: Governance-compliant disclosure of a planned sale; 10b5-1 adoption date is provided and signatures are in order.

The filing includes the 10b5-1 plan adoption date (11/25/2024), an explicit statement that the sale was pursuant to that plan, and an undertaking to provide detailed allocation of shares by execution price on request. The form is signed by an Attorney-in-Fact on behalf of the reporting person. From a governance perspective, the disclosure meets regulatory expectations for planned insider transactions and transparency about trade pricing ranges.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Maroney Dawn Christine

(Last) (First) (Middle)

1100 W. TOWN & COUNTRY RD.

SUITE 1600

(Street)

ORANGE CA 92868

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Alignment Healthcare, Inc. [ ALHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/13/2025		S(1)		30,000	D	$14.9036(2)	2,012,899	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Date of Rule 10b5-1 plan adoption: 11/25/2024

2. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $14.64 to $15.13. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

Remarks:

	/s/ Christopher J. Joyce, as Attorney-in-Fact, for Dawn C. Maroney	08/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Dawn C. Maroney report in the ALHC Form 4?

She reported a sale of 30,000 shares of Alignment Healthcare common stock on 08/13/2025 under a Rule 10b5-1 plan.

What price did the ALHC shares sell for in the reported transaction?

The weighted-average price was $14.9036, with individual trades ranging from $14.64 to $15.13 per share.

When was the 10b5-1 trading plan adopted for this transaction?

The 10b5-1 plan adoption date is 11/25/2024, as disclosed in the Form 4 explanation.

How many ALHC shares does the reporting person own after the sale?

2,012,899 shares are reported as beneficially owned following the transaction.

Will the filer provide details of how many shares sold at each price?

Yes, the filer states they will provide full information on the number of shares sold at each price within the disclosed range upon request.